Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.70 |
| ▸ | CA2 | P00918 | 3/20 | 0.70 |
| ▸ | CA7 | P43166 | 3/20 | 0.70 |
| ▸ | CA9 | Q16790 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | AGER | Q15109 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16269805 | 1.00 | CA1 (0.70) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL122306 | 1.00 | CA1 (0.70) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL508126 | 1.00 | CA1 (0.70) | CA1CA2CA7CA9MAPK1 | |
| Bicarbonate SCHEMBL17044691 | 0.94 | CA1 (0.64) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL397022 | 0.90 | CA1 (0.78) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL25300063 | 0.89 | CA1 (0.57) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL30590458 | 0.89 | CA1 (0.57) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL24207966 | 0.89 | CA1 (0.57) | CA1CA2CA7CA9MAPK1 | |
| Glycerin SCHEMBL3807616 | 0.88 | TSHR (0.65) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL23455700 | 0.86 | CA1 (0.54) | CA1CA2CA7CA9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-59076049-A | — | — | None | — | — | JP | disclosed |
| JP-1228997-A | — | — | None | — | — | JP | disclosed |
| JP-4257595-A | — | — | None | — | — | JP | disclosed |
| EP-4744668-A2 | POLYNUCLEOTIDE CONSTRUCTS | Sirius Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-04-23 | — | — | US | disclosed |
| EP-4709710-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12453785-B2 | Macrocyclic chelators and methods of use thereof | JANSSEN BIOTECH, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4592295-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-20250186456-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2025-06-12 | — | — | US | disclosed |
| US-20250084116-A1 | MIXTURE OF STEREOISOMERS OF A SULFATED GLYCOLIPID | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2025-03-13 | — | — | US | disclosed |
| US-4329289-A | Adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1982-05-11 | — | — | US | disclosed |
| US-4314085-A | Intermediates for preparing adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1982-02-02 | — | — | US | disclosed |
| US-4304721-A | Adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1981-12-08 | — | — | US | disclosed |
| US-4301300-A | ADRENERGIC BLOCKING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1981-11-17 | — | — | US | disclosed |
| US-4285873-A | ANTIANDROGENS | HOFFMANN-LA ROCHE INC. (US) | 1981-08-25 | — | — | US | disclosed |
| US-4281189-A | Sulfonamide intermediates for adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1981-07-28 | — | — | US | disclosed |
| US-4278608-A | Adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1981-07-14 | — | — | US | disclosed |
| US-4247710-A | THE 3'-HYDROXY, -BENZYLOXY, OR -HALO DERIVATIVES OF METHYL 4-((2'-HYDROXYPROPYL)OXY)PHENYLACETATE | HOFFMANN-LA ROCHE INC. (US) | 1981-01-27 | — | — | US | disclosed |
| US-4202978-A | ADRENERGIC BLOCKING AGENTS, HYPOTENSIVE, ANTISECRETORY, SPASMOLYTIC | HOFFMANN-LA ROCHE INC. (US) | 1980-05-13 | — | — | US | disclosed |
| EP-0005142-A1 | Phenylpiperazine derivatives, process for their preparation, intermediates for this purpose and medicaments containing such phenylpiperazine derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084116-A1 | MIXTURE OF STEREOISOMERS OF A SULFATED GLYCOLIPID | DEGS1, SGMS1, SGMS2 | CA1 2889/4885CA2 3446/4885CA7 3251/4885 |
| US-20250186456-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | KRAS, NRAS, TP53 | CA1 3584/4885CA2 3018/4885CA7 1870/4885 |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, HRAS | CA1 1541/4885CA2 1003/4885CA7 573/4885 |
| US-12453785-B2 | Macrocyclic chelators and methods of use thereof | CLASP1, CLTC, CD47 | CA1 306/4885CA2 1839/4885CA7 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.